Effect of nebulised L- and D-arginine on exhaled nitric oxide in steroid naive asthma

Chambers, D. C.; Ayres, J. G.
August 2001
Thorax;Aug2001, Vol. 56 Issue 8, p602
Academic Journal
Background--Nitric oxide (NO) is a product of the enzyme nitric oxide synthase (NOS) and is found in normal and asthmatic human airways. The administration of L-arginine results in an increase in airway NO production in asthmatic subjects. This is thought to occur because L-arginine is the substrate for NOS. However, studies in the systemic vasculature suggest that other mechanisms may be responsible. Methods--Eight patients with steroid naive asthma each received 2.5 g L-arginine, 2.5 g D-arginine, and 2.0% saline by ultrasonic nebuliser on separate days in a randomised, single blind manner. Exhaled NO was measured by chemiluminescence and spirometric tests were performed before and for 3 hours after each administration. The mean concentration of NO after exposure was calculated from the area under the curve. Results--L-arginine, D-arginine, and 2.0% saline induced a mean (95% CI) maximal bronchoconstriction of 11.9% (-1.7 to 25.4), 10.0% (2.8 to 17.2), and 8.5% (-2.5 to 19.5) of the starting forced expiratory volume in one second (FEV1), respectively. Exhaled NO declined in proportion to the degree of bronchoconstriction (r=0.60, p<0.01). Bronchoconstriction and the acute reduction in exhaled NO resolved within 15 minutes. The mean post-exposure concentration of NO was 15.75 parts per billion (ppb) after L-arginine, 15.16 ppb after D-arginine, and 12.74 ppb after 2.0% saline. The mean (95% CI) difference between L-arginine and placebo was 3.01 (0.32 to 5.7) ppb, between D-arginine and placebo 2.42 (0.10 to 4.74) ppb, and between L- and D-arginine 0.59 (-1.56 to 2.74) ppb. Conclusions--Exhaled NO decreased with acute bronchoconstriction and returned to baseline with the resolution of bronchoconstriction. Exhaled NO increased following the administration of both L-arginine and D-arginine. Since NOS is stereospecific, this finding suggests that the increase in exhaled NO is not entirely mediated through an increase in NOS enzyme activity. We suggest that arginine may react in a non-stereospecific fashion with reactive oxygen species present in asthmatic airways.


Related Articles

  • Asymmetric Dimethylarginine in Chronic Obstructive Pulmonary Disease (ADMA in COPD). Scott, Jeremy A.; Duongh, MyLinh; Young, Aaron W.; Subbarao, Padmaja; Gauvreau, Gail M.; Grasemann, Hartmut // International Journal of Molecular Sciences;Apr2014, Vol. 15 Issue 4, p6062 

    L-Arginine metabolism including the nitric oxide (NO) synthase and arginase pathways is important in the maintenance of airways function. We have previously reported that accumulation of asymmetric dimethylarginine (ADMA) in airways, resulting in changes in L-arginine metabolism, contributes to...

  • Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease. Ricciardolo, Fabio L.M.; Nijkamp, Frans P.; Folkerts, Gert // Current Drug Targets;Jun2006, Vol. 7 Issue 6, p721 

    In the respiratory tract, NO is produced by residential and inflammatory cells. NO is generated via oxidation of L-arginine that is catalysed by the enzyme NO synthase (NOS). NOS exists in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO derived...

  • Constitutive Nitric Oxide Synthase Is Present in Normal Human Keratinocytes. Baudouin, J. E.; Tachon, P. // Journal of Investigative Dermatology;Mar1996, Vol. 106 Issue 3, p428 

    Normal human keratinocytes in culture exhibit a nitric oxide synthase (NOS) activity ranging from 50 to 150 pmol/min/mg of protein. The enzyme is cytosolic and requires the presence of calcium, nicotinamide adenine dinucleotide phosphate, reduced form (NADPH), and flavin adenine dinucleotide....

  • Associations between endothelial nitric oxide synthase A/B, angiotensin converting enzyme I/D and serotonin transporter L/S gene polymorphisms with pulmonary hypertension in COPD patients. Ulasli, Sevinc; Eyuboglu, Fusun; Verdi, Hasibe; Atac, Fatma // Molecular Biology Reports;Oct2013, Vol. 40 Issue 10, p5625 

    Different biochemical pathways and cellular mechanisms play role in the pathogenesis of pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD). Alveolar hypoxia is not the only determinant of vascular remodeling, genetic factors are thought to have additive effects. We aimed...

  • Review: daily salmeterol increases non-fatal serious adverse events in chronic asthma. Cates, C. J. // Evidence Based Medicine;Feb2009, Vol. 14 Issue 1, p6 

    The article presents a review on the daily salmeterol increases non-fatal serious adverse events in chronic asthma. The review analyzes the effect of the daily salmeterol in the chronic asthma patients. Studies compared salmeterol with placebo or short-acting ß-antagonists in patients with...

  • l-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Peters, Harm; Border, Wayne A.; Noble, Nancy A. // Kidney International;Jun1999, Vol. 55 Issue 6, p2264 

    L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Background. Mesangial cell lysis in the antithymocyte serum (ATS)-induced model of glomerulonephritis is dependent on the generation of cytotoxic nitric oxide (NO)...

  • Failure of sputum eosinophilia after eotaxin inhalation in asthma. Bumbocea, D.; Scheerens, J.; Mann, B. S.; Stirling, R. G.; Chung, K. F. // Thorax;May2004, Vol. 59 Issue 5, p372 

    Background: Eotaxin is a chemokine specific for eosinophils and may play an important role in eosinophil recruitment in asthma. The effects of eotaxin inhalation on sputum and blood eosinophils, exhaled nitric oxide (NO), and bronchial responsiveness were determined. Methods: Eotaxin was...

  • Mild persistent asthma and inhaled corticosteroids: is daily therapy really necessary? Bauchner, Howard // Archives of Disease in Childhood;Oct2005, Vol. 90 Issue 10, p1094 

    This article cites a study on the treatment of mild persistent asthma, which was published in the May 6, 2005 issue of the "Journal Watch Pediatrics and Adolescent Medicine." In this double-blind trial, researchers randomized 225 adults with mild persistent asthma to receive twice-daily inhaled...

  • Research news.  // Update;5/19/2005, Vol. 70 Issue 5, p6 

    This article presents research news related to various diseases. Mild persistent asthma can be successfully treated with short courses of corticosteroids when needed, rather than daily therapy. The U.S. researchers found many patients with the condition already use steroids intermittently,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics